ArticleOncology letters2017
DNA topoisomerase IIα and Ki67 are prognostic factors in patients with hepatocellular carcinoma.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Diffusion-Weighted Imaging as a Quantitative Imaging Biomarker for Predicting Proliferation Rate in Hepatocellular Carcinoma: Developing a Radiomics Nomogram.Journal of computer assisted tomographyTrial
- Prediction of Ki-67 expression in hepatocellular carcinoma with machine learning models based on intratumoral and peritumoral radiomic features.World journal of gastrointestinal oncology · 2025Article
- Preoperative assessment of Ki-67 expression in hepatocellular carcinoma using a multi-parametric spectral CT approach.Quantitative imaging in medicine and surgery · 2025Article
- A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers.Frontiers in immunology · 2025Article
- Nomogram based on the neutrophil-to-lymphocyte ratio and MR diffusion quantitative parameters for predicting Ki67 expression in hepatocellular carcinoma from a prospective study.Scientific reports · 2024Article
- A predictive model based on radiomics, clinical features, and pathologic indicators for disease-free survival after liver transplantation for hepatocellular carcinoma: a 7-year retrospective study.Journal of gastrointestinal oncology · 2024Article
- Role of the Clinical Features and MRI Parameters on Ki-67 Expression in Hepatocellular Carcinoma Patients: Development of a Predictive Nomogram.Journal of gastrointestinal cancer · 2024Article
- Preoperative prediction of microvascular invasion classification in hepatocellular carcinoma based on clinical features and MRI parameters.Oncology letters · 2024Article
- Predicting Ki-67 expression in hepatocellular carcinoma: nomogram based on clinical factors and contrast-enhanced ultrasound radiomics signatures.Abdominal radiology (New York) · 2024Article
- MRI Radiomics Combined with Clinicopathological Factors for Predicting 3-Year Overall Survival of Hepatocellular Carcinoma After Hepatectomy.Journal of hepatocellular carcinoma · 2024Article
- Radiomics analysis of R2* maps to predict early recurrence of single hepatocellular carcinoma after hepatectomy.Frontiers in oncology · 2024Article
- Tumor-derived proliferative CTCs and CTC clusters predict aggressiveness and early recurrence in hepatocellular carcinoma patients.Cancer medicine · 2023Article
- Intratumoral and peritumoral radiomics model based on abdominal ultrasound for predicting Ki-67 expression in patients with hepatocellular cancer.Frontiers in oncology · 2023Article
- Gadoxetic acid-enhanced MRI combined with T1 mapping and clinical factors to predict Ki-67 expression of hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Protective Effects of Naringin-Dextrin Nanoformula against Chemically Induced Hepatocellular Carcinoma in Wistar Rats: Roles of Oxidative Stress, Inflammation, Cell Apoptosis, and Proliferation.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Nomogram development and validation to predict Ki-67 expression of hepatocellular carcinoma derived from Gd-EOB-DTPA-enhanced MRI combined with T1 mapping.Frontiers in oncology · 2022Article
- TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib.American journal of cancer research · 2022Article
- Noninvasively predict the micro-vascular invasion and histopathological grade of hepatocellular carcinoma with CT-derived radiomics.European journal of radiology open · 2022Article
- Nomogram Based on CT Radiomics Features Combined With Clinical Factors to Predict Ki-67 Expression in Hepatocellular Carcinoma.Frontiers in oncology · 2022Article
- Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study was designed to determine the significance of DNA topoisomerase IIa (TopoIIα) and Ki67 in hepatocellular carcinoma cells (HCCs). The present study included 353 patients with HCC. The association of clinicopathological data with the expression of TopoIIα and Ki67 by immunohistochemistry was analyzed by χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.